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A B S T R A C T
Age-re​lated changes in liver func​tion have a sig​nif ​i​cant im​pact on sys ​temic ag ​ing and sus ​cep ​ti​bil​ity to age-
re​lated dis ​eases. Nu​tri​ent sens ​ing path ​ways have emerged as im​por ​tant tar ​gets for the de​vel​op​ment of
drugs that de​lay ag ​ing and the on​set age-re​lated dis ​eases. This sup​ports a cen ​tral role for the he​patic reg ​u​-
la​tion of me​tab ​o​lism in the as ​so​ci​a​tion be​tween nu​tri​tion and ag ​ing. Re​cently, a role for liver si​nu​soidal
en ​dothe​lial cells (LSECs) in the re​la​tion ​ship be​tween ag ​ing and me​tab ​o​lism has also been pro ​posed. Age-
re​lated loss of fen ​es ​tra​tions within LSECs im​pairs the trans ​fer of sub​strates (such as lipopro ​teins and in ​-
sulin) be​tween si​nu​soidal blood and he​pa​to ​cytes, re​sult​ing in post-pran ​dial hy​per ​lipi​demia and in ​sulin re​-
sis​tance. Tar​geted drug de​liv ​ery meth ​ods such as nanopar ​ti​cles and quan ​tum dots will fa​cil​i​tate the di​rect
de​liv ​ery of drugs that reg ​u​late fen ​es ​tra​tions in LSECs, pro ​vid ​ing an in ​no​v​a​tive ap ​proach to ame​lio ​rat​ing
age-re​lated dis ​eases and in ​creas ​ing healthspan.
© 2018.
1. Introduction
Ad​vances in the treat​ment and pre​ven ​tion of in ​fec​tious dis ​eases,
to ​gether with in ​creased stan​dards of liv ​ing have led to a rapid in ​-
crease in life ex ​pectancy over the last cen ​tury [1]. How ​ever, this has
dri​ven a sig​nif ​i​cant in ​crease in the num​ber of older peo ​ple with mul​-
ti​mor ​bid ​ity and dis ​abil​ity that im​pair qual​ity of life and pro ​duc​tiv ​ity
[2]. There​fore, re​search in ag ​ing bi​ol​ogy largely fo ​cusses on de​lay ​ing ​
Abbreviations: AMPK, AMP-ac​ti​vated pro ​tein ki​nase; Cd, cad ​mium; CR, caloric
re​stric​tion; FOXO, fork ​head box O tran ​scrip ​tion fac​tor; FSA, formalde​hyde treated
BSA/​HAS; GH, growth hor ​mone; HA, hyaluro ​nan; HOMA-IR, home​o​sta​tic model
of as ​sess​ment on in ​sulin re​sis​tance; IGF-1, in ​sulin-like growth fac​tor 1; IRS1, in ​-
sulin re​cep ​tor sub​unit 1; ISS, in ​sulin/​IGF-1 sig​nal​ing; LKB1, liver ki​nase B1;
LSEC, liver si​nu​soidal en ​dothe​lial cell; mTOR, mech ​a​nis ​tic tar ​get of ra​pamycin;
MEND, mul​ti​func​tional en ​ve​lope-like nanocap ​sule de​vice; NAD , nicoti​namide
ade​nine din ​u​cleotide; NAM, nicoti​namide; NMN, nicoti​namide mononu ​cleotide;
NR, nicoti​namide ri​bo​side; PEG, poly ​eth ​yl​ene gly ​col; PINP, pro-col​la​gen I N-ter ​-
mi​nal pep ​tides; PI3K, phos ​phatidyli​nos ​i​tol 3-ki​nase; PKB, pro ​tein ki​nase B; QDs,
quan ​tum dots; S, sul​phide; SIRT1, sir​tuin 1; TRAIL, TNF-re​lated apop ​to ​sis in ​duc​-
ing lig ​and; Te, tel​luride.
⁎ Corresponding author at: Biogerontology Group, Concord General Hospital,
ANZAC Research Institute, Australia.
Email address: victoria. ​cogger@​sydney.​edu. ​au (V.C. Cogger)
ag ​ing in or ​der to in ​crease healthspan, the pe​riod of life spent free
from, or with lim​ited, dis ​ease bur ​den [3,4].
2. Aging and the liver
Ag​ing is usu​ally con ​sid​ered to be a process of grad ​ual phys ​i​o​log ​i​-
cal de​te​ri​o​ra​tion ex ​pe​ri​enced over time by most liv ​ing things, lead ​ing
to in ​creased risk of dis ​ease and death. Ag​ing is a het​ero ​ge​neous and
het​e​rochronic process that can be dif ​fi​cult to eval​u​ate be​cause there
are dif ​fer ​ent rates of ag ​ing be​tween species and within in ​di​vid ​u​als of
the same species, as well as be​tween tis ​sues in the same or ​gan ​ism [5].
This het​ero ​gene​ity has in part pre​vented the iden ​ti​fi​ca​tion of a sin​gle
marker and/​or cause of ag ​ing, how ​ever there are sev​eral bi​o​log ​i​cal
processes that have been iden ​ti​fied as mod ​u​la​tors of the ag ​ing
process [5]. De​scribed as the “hall​marks of ag ​ing”, these processes
in ​clude: ge​nomic in ​sta​bil​ity, telom​ere at​tri​tion, epi​ge​netic al​ter ​ations,
loss of pro ​teosta​sis, dereg ​u​lated nu​tri​ent sens ​ing, mi​to ​chon ​dr ​ial dys ​-
func​tion, cel​lu ​lar senes ​cence, stem cell ex ​haus ​tion and al​tered in ​ter ​-
cel​lu ​lar com​mu ​ni​ca​tion [6].
One method of eval​u​at​ing the rate of ag ​ing that en ​com​passes
many of its man ​i​fes ​ta​tions is the “tran ​scrip ​tome age” [7]. Age-re​lated
changes in the “tran ​scrip ​tome” of whole blood cor ​re​late bet​ter than
chrono ​log ​i​cal age with risk fac​tors for car ​diometa​bolic dis ​ease and
death in ​clud ​ing cho ​les ​terol lev ​els, body mass in ​dex, blood pres ​sure
and fast​ing glu ​cose [8,9]. Stud​ies such as these high ​light the con ​ver
https://doi.org/10.​1016/​j. ​addr. ​2018.​09.​006
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gence of many ag ​ing mech ​a​nisms with car ​diometa​bolic dys ​func​tion
[10]. This im​por ​tance of meta​bolic path ​ways in ag ​ing bi​ol​ogy is ev ​i​-
denced by the fact that the most ro ​bust in ​ter ​ven ​tion that de​lays ag ​ing
is the nu​tri​tional in ​ter ​ven ​tion called “caloric re​stric​tion” (CR). First
de​scribed in 1935 by Clive McKay et al. [11], CR is usu​ally de​fined
as a re​duc​tion in to ​tal calo ​rie in ​take by 20-40% with mi​cronu ​tri​ent
sup​ple​men ​ta​tion to pre​vent spe​cific mal​nu​tri​tion dis ​or ​ders. Life​long
CR in ​creases mean and max ​i​mal lifes ​pan by 30-50% in ro ​dents,
dogs, flies, yeast, worms, mon ​keys and prokary ​otes [2]. There is also
lim​ited ev ​i​dence in hu​mans that CR in ​flu ​ences life ex ​pectancy and
re​duces the de​vel​op​ment of dis ​eases [12] as well as the ag ​ing process
it​self [13]. Mice that are sub​jected to CR are leaner, more in ​sulin sen​-
si​tive, glu ​cose tol​er ​ant and have re​duced in ​ci​dence of dis ​ease [29].
The ef ​fects of CR on ag ​ing are con ​served across a range of species,
in ​di​cat​ing that there are fun ​da​men ​tal cel​lu ​lar path ​ways link ​ing nu​tri​-
tion with ag ​ing and health. Re​search in this area has led to the iden ​ti​-
fi​ca​tion of sev​eral key nu​tri​ent sens ​ing path ​ways that reg ​u​late ag ​ing
(in ​sulin/​IGF1/​GH sig​nal​ing, SIRT1, AMPK and mTOR) [2], which
in ver ​te​brates are most strate​gi​cally lo ​cated in the liver, be​cause it is
the mas ​ter reg ​u​la​tor or ​gan of sys ​temic me​tab ​o​lism.
The liver reg ​u​lates most meta​bolic path ​ways in ​clud ​ing glu ​cose
me​tab ​o​lism via gly ​col​y​sis, glu ​cose up​take and glu ​co ​neo ​ge​n​e​sis [14];
the for ​ma​tion and pack ​ag ​ing of cho ​les ​terol and other lipids; and in ​-
sulin sen​si​tiv ​ity (Table 1) [15,16]. In ​gested sub​stances that are ab ​-
sorbed from the gut travel to the liver via the por ​tal vein [17], which ​
Table 1
Ag​ing and he​patic me​tab ​o​lism, ef ​fects of caloric re​stric​tion and drug treat​ments
Summary of age-related changes in the liver and
treatments with caloric restriction and drugs that delays
the aging process Reference
Increased protein synthesis and burden of misfolded
proteins producing oxidative stress and damage
occur in the liver proteome of aging mice. This
burden is reduced following 40% CR or rapamycin
[189]
Increased lipogenesis gene expression, cholesterol
synthesis and lipid storage are observed in the aging
mice liver. CR promotes the reprogramming of mice
liver lipidome
[190–192]
Decreased hepatic autophagy has been demonstrated in
multiple species with age, impairment leads to
accumulation intracellular oxidative proteins, lipid
droplets, lipofuscin and impaired mitochondrial
function. Hepatic amino acid, glucose and free fatty
acid metabolism are impaired. Acceleration of
hepatic related diseases. Resveratrol (200 mg/kg)
and 30% CR have been shown to promote SIRT1
mediated autophagy and improve oxidative protein
stress.
[83,193,194]
Insulin signalling and sensitivity is reduced in aging
rats and mediated via visceral fat content. Treatment
with resveratrol, Metformin and CR promote
increased insulin sensitivity in aged rats
[65,195–198]
Hepatic glycolysis, glycogenesis and glucose uptake
are all decreased with aging. FOXO genetic
manipulation demonstrates its role in hepatic gene
regulation of gluconeogenesis, glycolysis and
lipogenesis. SIRT1 and PGC-1α activation promote
increased gluconeogenesis and reduced glycolysis in
the liver
[65,96,196,199,200]
SIRT1 and mitochondrial biogenesis are reduced in
aging mice; SIRT1-mediated HIF-1α and PGC-1α
activity regulate mitochondrial biogenesis. CR and
resveratrol treatments promote improved
mitochondrial function in aging mice
[44,98,178]
Aging mice livers demonstrate increased inflammation,
cellular stress, and fibrosis, with decreased
apoptosis, xenobiotic metabolism, cell-cycling and
DNA replication genomic profiles. 40% CR for a
month was shown to improve these profiles in mice.
[96]
also con ​tains pan ​cre​atic hor ​mones in ​clud ​ing in ​sulin, glucagon and C-
pep ​tide [18,19]. The he​patic mi​crovas ​cu ​la​ture is highly spe​cial​ized to
op​ti​mize the bidi​rec​tional ex ​change of sub​strates be​tween blood and
he​pa​to ​cytes. The en ​dothe​lial cells that line this si​nu​soidal mi​crovas ​-
cu ​la​ture (the “he​patic si​nu​soids”) are called liver si​nu​soidal en ​dothe​-
lial cells (LSEC) and are per ​fo ​rated with pores called “fen ​es ​tra​tions”
that fa​cil​i​tate size-se​lec​tive siev​ing of blood-borne mol​e​cules for up​-
take by he​pa​to ​cytes [20,21]. The term “pseudo ​cap ​il​lar ​iza​tion” refers
to age-re​lated changes in the LSEC in ​clud ​ing a re​duc​tion in the size
and num​ber of fen ​es ​tra​tions, which leads to im​paired up​take of some
sub​strates. Old age is as ​so​ci​ated with re​duc​tion in liver me​tab ​o​lism
due to three main fac​tors: re​duced meta​bolic ca​pac​ity due to di​min ​-
ished liver size and/​or en ​zyme ac​tiv ​ity; de​creased liver blood flow;
and re​duced trans ​fer of metabo ​lites and mol​e​cules from the si​nu​soids
to the he​pa​to ​cytes [22,23]. To ​gether, these changes im​pact many
facets of he​patic me​tab ​o​lism of sub​strates such as lipopro ​teins, drugs
and in ​sulin [24–26] thus po​ten ​tially con ​tribut​ing to in ​sulin re​sis​tance,
vas ​cu ​lar dis ​ease and ad ​verse drug re​ac​tions [7,27,28].
Here we dis ​cuss these two he​patic drug tar ​gets – nu​tri​ent sens ​ing
path ​way in he​pa​to ​cytes; and fen ​es ​tra​tions in LSECs – that might im​-
pact on sys ​temic and he​patic ag ​ing. We also dis ​cuss the pos ​si​bil​ity of
us ​ing nanomed ​i​cines to pre​cisely de​liver fen ​es ​tra​tion-ac​tive agents
di​rectly to the LSECs.
3. Targeting the nutrient sensing pathways
Nu​tri​ent sens ​ing path ​ways reg ​u​late adap ​tive cel​lu ​lar re​sponses to
chang ​ing nu​tri​ent avail​abil​ity such as famine or food ex ​cess. Dur​ing
times of nu​tri​ent scarcity, these path ​ways pro ​mote the sur​vival and
re​silience of an or ​gan ​ism at the cost of re​duced re​pro ​duc​tive ca​pac​ity.
Pre​sum​ably these path ​ways have evolved to pro ​mote re​pro ​duc​tion
only when there are suf​fi​cient nu​tri​ents to en ​sure the sur​vival of off ​-
spring. In mul​ti​cel​lu ​lar or ​gan ​isms nu​tri​ent sens ​ing path ​ways form
com​plex net​works that de​tect, or ​ga​nize, use, re​con ​sti​tute and me​tab ​o​-
lize nu​tri​ents [29]. The down​stream phys ​i​o​log ​i​cal con ​se​quences of
ac​ti​vat​ing or an ​tag ​o​niz​ing these path ​ways (for ex ​am​ple by CR, or
drugs that are thought to mimic CR) are shown in Table 1 [40]. Ma​-
nip ​u​la​tion of these path ​ways through CR or ge​netic in ​ter ​ven ​tions has
been shown to al​ter the bi​o​log ​i​cal process of ag ​ing, me​dian and max ​-
i​mal lifes ​pans and the in ​ci​dence of many age-re​lated dis ​eases. The
four canon ​i​cal nu​tri​ent sens ​ing path ​ways in ​ter ​act with each other and
share many down​stream tar ​gets that reg ​u​late cel​lu ​lar processes that
are crit​i​cal for ag ​ing in ​clud ​ing mi​to ​chon ​dr ​ial bio ​gen ​e​sis, cel​lu ​lar me​-
tab ​o​lism, au ​tophagy, DNA re​pair and ex ​pres ​sion, and trans ​la​tion
(Fig​ure 1).
With in ​creas ​ing age, there are changes in the ex ​pres ​sion and ac​tiv ​-
ity of the four nu​tri​ent sens ​ing path ​ways: in ​sulin/​IGF-1, mTOR,
AMPK, and the Sir​tuin/​NAD  path ​ways [16,30,31]. Within the key
or ​gans in ​volved in home​o​sta​tic meta​bolic reg ​u​la​tion – liver, pan ​-
creas, mus ​cle and fat – these changes are as ​so​ci​ated with other ag ​ing
processes such as ox​ida​tive stress [32] and in ​flam​ma​tion [29,33,34].
To ​gether these processes in these or ​gans con ​tribute to im​paired sys ​-
temic me​tab ​o​lism, which in turn is linked mech ​a​nis ​ti​cally with di​a​-
betes, car ​dio ​vas ​cu ​lar dis ​ease, can ​cers and neu ​rode​gen ​er ​a​tion
[5,31,33,35]. Al​though the ma​jor in ​ter ​ven ​tions used are CR and ge​-
netic over ​ex ​pres ​sion or knock ​out mod ​els [36,37], re​cently phar ​ma​co ​-
log ​i​cal ma​nip ​u​la​tion of these path ​ways with agents such as met​-
formin, ra​pamycin and resver ​a​trol, has been shown to de​lay the ag ​ing
process, at least in lab ​o​ra​tory an ​i​mal mod ​els [38–40].
Ther ​a​peu ​tic agents re​ca​pit​u​late the ef ​fects of CR on ag ​ing have
been termed “CR-mimet​ics” [41] which pri​mar ​ily tar ​get in ​di​vid ​ual
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have been used to treat in ​di​vid ​ual dis ​eases in the past, it is pos ​si​ble
that their ben ​e​fi​cial ef ​fect is in part sec​ondary to de​lay the ef ​fect of
ag ​ing on these dis ​eases. More​over, in some stud​ies in an ​i​mal mod ​els,
CR mimet​ics have been found to in ​crease me​dian and max ​i​mal lifes ​-
pan, prob ​a​bly by de​lay ​ing the on​set of ag ​ing [16,42,43].
The main fea​tures of these nu​tri​ent sens ​ing path ​ways are as fol​-
lows:
3.1. Mechanistic target of rapamycin (mTOR)
mTOR is a ser​ine/​thre​o​nine pro ​tein ki​nase that reg ​u​lates cell
growth, pro ​lif ​er ​a​tion, motil​ity, pro ​tein syn​the​sis and au ​tophagy.
mTOR in ​te​grates in ​put from var ​i​ous path ​ways, in ​clud ​ing in ​sulin and
IGF-1, and re​sponds to di​etary pro ​tein, par ​tic​u​larly the branched-
chain amino acids. mTOR ex ​ists in two dif ​fer ​ent com​plexes
mTORC1 and mTORC2, which are dif ​fer ​en ​ti​ated by their ac​ces ​sory
pro ​teins, Rap ​tor and Ric​tor, and only mTORC1 is sen​si​tive to amino
acids [44]. Ra​pamycin is a po​tent in ​hibitor of mTOR that was ini​-
tially uti​lized as an im​muno ​sup​pres ​sive drug for pa​tients fol​low ​ing
re​nal trans ​plants. It has now been as ​so​ci​ated with in ​creased lifes ​pan
in mice fed stan​dard di​ets [45,46] and hu​man stud​ies into the ef ​fects
of ra​pamycin on healthy el​derly pa​tients are cur ​rently be​ing per ​-
formed [30,47].
3.2. 5' Adenosine monophosphate- ​activated protein kinase (AMPK)
AMPK reg ​u​lates cel​lu ​lar up​take of glu ​cose, β-ox​i​da​tion of fatty
acids, the glu ​cose trans ​porter 4 (GLUT4), and mi​to ​chon ​dr ​ial bio ​gen ​-
e​sis. AMPK is ac​ti​vated in re​sponse to in ​creased cel​lu ​lar AMP:ATP
ra​tio. CR is as ​so​ci​ated with in ​creased AMPK ac​tiv ​ity as a con ​se​-
quence of re​duced en ​ergy in ​take. Met​formin en ​hances lifes ​pan in
mice and this is ac​com​pa​nied by an in ​crease in AMPK ac​tiv ​ity [39].
In hu​mans, met​formin has been shown to re​duce the pro ​gres ​sion of
di​a​betic im​pair ​ment of glu ​cose tol​er ​ance by 31%, re​duce ath ​er ​o​scle​-
ro ​sis de​vel​op​ment [48–50] and a sys ​tem​atic re​view has demon ​strated
im​proved car ​dio ​vas ​cu ​lar mor ​tal​ity by 25% [51,52]. Ad​di​tion ​ally a re​-
cent sys ​tem​atic re​view found that met​formin pro ​motes a sig​nif ​i​cantly
lower mor ​tal​ity in di​a​betic pa​tients com​pared to non-di​a​bet​ics and
also di​a​bet​ics that were not on met​formin [53]. Hu​man ob​ser​va​tional
stud​ies have con ​cluded that met​formin de​creases the risk of the most
com​mon dis ​eases of ag ​ing: car ​dio ​vas ​cu ​lar dis ​ease [54–56], can ​cer
[57], de​pres ​sion [58], frailty [54], mild cog ​ni​tive im​pair ​ment [59] and
de​men ​tia [60,61]. Clin ​i​cal tri​als in hu​mans to eval​u​ate its ef ​fects on
dis ​ease sus ​cep ​ti​bil​ity and ag ​ing bi​ol​ogy (in ​cluded tran ​scrip ​tome) are
planned.
3.3. Sirtuin pathway (SIRT1)
Sir​tu ​ins are class III hi​s ​tone deacety ​lases that re​quire NAD  as a
co ​fac​tor. CR in ​creases cel​lu ​lar NAD  as a con ​se​quence of re​duced
en ​ergy in ​take, thereby ac​ti​vat​ing sir​tu ​ins. While the sir​tuin fam​ily
con ​sists of seven mem​bers [62], in mam​mals, the key ag ​ing ho​molog
is SIRT1 which deacety ​lates key hi​s ​tone residues in ​volved in the reg ​-
u​la​tion of tran ​scrip ​tion and mul​ti​ple non-hi​s ​tone pro ​tein tar ​gets rel​e​-
vant to ag ​ing (p53, FOXO, PGC-1α, NF-κB) [37,63]. A num​ber of
phar ​ma​co ​log ​i​cal agents that al​loster ​i​cally ac​ti​vate SIRT1 de​lay ag ​ing
(Sir​tuin Ac​ti​vat​ing Com​pounds, known as STACs) in ​clud ​ing resver ​a​-
trol and SRT2014 [40,64–67]. STACs pro ​mote al​losteric ac​ti​va​tion of
SIRT1 and dif ​fer in their po​tency and op​ti​miza​tion in the ac​ti​va​tion
of sir​tuin [68]. STACs mimic CR, in ​crease mi​to ​chon ​dr ​ial func​tion ​
and pro ​tect against meta​bolic and car ​dio ​vas ​cu ​lar dis ​ease pro ​gres ​sion
by re​duc​ing meta​bolic risk fac​tors [66,68]. No​tably resver ​a​trol in ​-
creased lifes ​pan in mice fed a high fat diet [65] but not in mice on
stan​dard chow where only health ben ​e​fits were ob​served [46,69].
This sug​gests that ac​ti​va​tion of the SIRT1 path ​way may have its
great​est ef ​fect on ag ​ing where there is high en ​ergy in ​take and great​est
in ​hi​bi​tion of SIRT ac​tiv ​ity. In ad ​di​tion, ac​ti​va​tion of SIRT1 with
resver ​a​trol treat​ment in vitro pro ​moted en ​dothe​lial pro ​tec​tion via
KLF-2 and MAPK5 [70].
A com​pre​hen ​sive re​view of hu​man clin ​i​cal tri​als, has demon ​-
strated in ​con ​sis​tent find ​ings in older peo ​ple, with some show ​ing
health ben ​e​fits, par ​tic​u​larly in older hu​mans with mul​ti​mor ​bidi​ties
such as type II di​a​betes, non-al​co ​holic fatty liver dis ​ease (NAFLD)
and coro ​nary artery dis ​ease [71–78]. The dose, du​ra​tion and the
source of resver ​a​trol has var ​ied across many of the tri​als and might
ac​count for some of the in ​con ​sis​ten ​cies seen in ag ​ing hu​man stud​ies.
More re​cently nicoti​namide mononu ​cleotide (NMN), and nicoti​-
namide ri​bo​side (NR), biosyn​thetic NAD  metabo ​lites have been in ​-
ves ​ti​gated for their abil​ity to aug ​ment NAD  blood lev ​els [79].
3.4. Insulin/​IGF- ​1signaling pathway (ISS)
The in ​sulin/ IGF-1 sig​nal​ing path ​way is con ​tin ​u​ously mod ​u​lated
by di​etary nu​tri​ent sta​tus: plasma con ​cen ​tra​tions of pro​tein (IGF-1)
and sug​ars (in ​sulin) and ad ​di​tion ​ally by the lev ​els of cir ​cu ​lat​ing
growth hor ​mone (GH) [30]. In ​sulin re​lease is stim​u​lated by glu ​cose
and branched-chain amino acids. GH stim​u​lates he​patic pro ​duc​tion of
IGF-1 and acts on the IIS path ​way to mod ​u​late in ​sulin sen​si​tiv ​ity
[80]. Lower lev ​els of in ​sulin, IGF-1 and GH in ​duced by ei​ther ge​-
netic vari​abil​ity or low en ​ergy di​ets are as ​so​ci​ated with in ​creased
lifes ​pan across taxa and in ​clud ​ing hu​mans [36].
3.5. Recent additions to the classic pathways
Au​tophagy is an es ​sen​tial cel​lu ​lar process that pro ​motes cell sur​-
vival, es ​pe​cially as a cel​lu ​lar star​va​tion re​sponse, and reg ​u​lates
home​osta​sis. Au​tophagy is up​reg ​u​lated in the set​ting of low ATP and
in ​sulin, re​duced growth fac​tor stim​u​la​tion and JNK1-Be​clin-1 de​pen ​-
dent cel​lu ​lar stress [81–84]. It fa​cil​i​tates the degra​da​tion of un​nec​es ​-
sary and dys ​func​tional cel​lu ​lar prod ​ucts, lib ​er ​at​ing cel​lu ​lar stores of
en ​ergy [29,85]. It has pre​vi​ously been high ​lighted in a re​view by
Gra​cia-San​cho, et al. [81] that au ​tophagy has an im​por ​tant role in in ​-
hibit​ing the de​vel​op​ment of liver dis ​eases such as NAFLD, how ​ever
hall​marks of NAFLD: hy​per ​glycemia and im​paired he​pa​to ​cel​lu ​lar
clear ​ance of lipids im​pairs au ​tophagy, sug​gest​ing that tar ​get​ing au ​-
tophagy path ​ways may be ben ​e​fi​cial in the treat​ment of NAFLD and
other fatty liver dis ​or ​ders.
An​other re​cent po​ten ​tial ad ​di​tion to these four clas ​si​cal nu​tri​ent-
sens ​ing path ​ways is Fi​brob ​last Growth Fac​tor 21 (FGF21). FGF21 is
pro ​duced by the liver and is in ​creased in re​sponse to acute star​va​tion,
with a re​cent study show ​ing that low pro ​tein in ​take is the ma​jor stim​-
u​lant for its ex ​pres ​sion and blood lev ​els [86,87]. It reg ​u​lates sev​eral
meta​bolic func​tions (glu ​co ​neo ​ge​n​e​sis, mi​to ​chon ​dr ​ial ac​tiv ​ity, ke​to ​ge​-
n​e​sis, lipid me​tab ​o​lism) which im​pact on age-re​lated health. FGF21
in ​ter ​acts with the other nu​tri​ent-sens ​ing path ​ways by ac​ti​vat​ing
AMPK and SIRT1 [88], sug​gest​ing a key role for FGF21 in link ​ing
nu​tri​tion and ag ​ing. Para​dox​i​cally in hu​mans, higher lev ​els of FGF21
are as ​so​ci​ated with obe​sity and di​a​betes, prob ​a​bly re​flect​ing FGF21
re​sis​tance in these con ​di​tions. The role of FGF21 in ag ​ing and nu​tri​-
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4. Targeting the liver in aging
As de​scribed above, the liver is a key reg ​u​la​tor of me​tab ​o​lism,
with sig​nif ​i​cant age-re​lated changes in func​tion sec​ondary to re​duced
liver size and en ​zyme ac​tiv ​ity, blood flow and transendothe​lial trans ​-
fer [20,22,23,90–93]. This im​pairs detox ​i​fi​ca​tion and clear ​ance of
var ​i​ous en ​do​bi​otics (e.g. lipopro ​teins and in ​sulin) [94] and xeno ​bi​-
otics (e.g. drugs, neu ​ro ​tox ​ins and car ​cino ​gens) [95]. Many processes
con ​tribute to re​duced meta​bolic en ​zyme ac​tiv ​ity and cel​lu ​lar dam​age
in the ag ​ing liver, in ​clud ​ing the ef ​fects of ag ​ing on ox​ida​tive stress,
in ​flam​ma​tion, stress re​sponses [96], au ​tophagy and apop ​to ​sis [96,97],
and mi​to ​chon ​dr ​ial func​tion [98]. The re​duc​tion in blood flow to the
liver re​flects a gen ​eral down reg ​u​la​tion of splanch ​nic blood flow in
all ab ​dom​i​nal or ​gans rather than any spe​cific he​patic ef ​fects on vas ​-
cu ​lar re​sis​tance. The re​duc​tion in the trans ​fer of sub​strates be​tween
blood and he​pa​to ​cytes oc​curs mainly as a re​sult of the loss of fen ​es ​-
tra​tions as ​so​ci​ated with pseudo ​cap ​il​lar ​iza​tion [2,24,25,94,95,99]. All
these ag ​ing liver changes will im​pact on the re​spon​sive​ness and ac​-
tiv ​ity of the nu​tri​ent sens ​ing path ​ways.
Age-re​lated changes in liver cells also con ​tribute to the in ​creas ​ing
risk of the de​vel​op​ment of liver dis ​eases with older age. The ac​cu ​mu ​-
la​tion of ox​ida​tive stress and age-re​lated changes in in ​flam​ma​tion fa​-
vors the pro ​gres ​sion to ​wards NAFLD, steato​hep ​ati​tis and he​pa​to ​cel​-
lu ​lar car ​ci​noma [100]. The de​vel​op​ment of NAFLD in ​volves im​pair ​-
ment of LSEC func​tions through im​paired reg ​u​la​tion of ni​tric ox​ide
syn​thase and loss of fen ​es ​tra​tions, with these fea​tures de​vel​op​ing
prior to the rise seen in in ​flam​ma​tory mark ​ers [101–103]. This sug​-
gests that tar ​get​ing LSECs may, in ad ​di​tion to pro ​mot​ing healthy ag ​-
ing, be rel​e​vant to pre​vent​ing the de​vel​op​ment of NAFLD and its
pro ​gres ​sion to steato​hep ​ati​tis (Fig. 1).
4.1. Liver sinusoidal endothelial cells
LSECs have a highly spe​cialised mor ​phol​ogy. They are per ​fo ​rated
by nu​mer ​ous nano-holes/​pores [104–106], called fen ​es ​tra​tions, with
di​am​e​ters in the range 50-200 nm. More​over, there is no un​der ​ly ​ing
base​ment mem​brane in the ex ​tra​cel​lu ​lar space of Disse. LSECs pos ​-
sess highly ef ​fi​cient en ​do​cytic ca​pac​ity, tran ​scel​lu ​lar trans ​porta​tion
and im​mune-me​di​ated path ​ways [107–111] that also con ​tribute to the
trans ​fer of sub​strates be​tween the blood and space of Disse. LSECs ​
re​tain blood cells within the si​nu​soidal lu ​men while al​low ​ing the bi-
di​rec​tional pas ​sage through the fen ​es ​tra​tions of sub​stances such as
dis ​solved or al​bu​min-bound drugs, pro ​teins, lipopro ​teins, and small
viruses (Fig. 2). Lit​tle is known about the dy​namic struc​ture and reg ​-
u​la​tion of fen ​es ​tra​tions. To date the ma​jor ​ity of stud​ies on LSEC fen ​-
es ​tra​tions have uti​lized elec​tron mi​croscopy and fixed cells or tis ​sue,
but new su​per-res ​o​lu ​tion op​ti​cal meth ​ods are now avail​able
[112–116], which can vi​su​al​ize fen ​es ​tra​tions in un​fixed and/​or live
LSEC, and their re​sponses to stim​uli over time [112,115]. This will
fa​cil​i​tate the dis ​cov ​ery and test ​ing of drugs that can in ​flu ​ence fen ​es ​-
tra​tions.
LSEC are po​tent scav​engers, be​long ​ing to the fam​ily of “scav​-
enger en ​dothe​lial cells” [110], which also in ​cludes bone mar ​row si​-
nu​soidal en ​dothe​lial cells [117,118] and chori​o​cap ​il​laris en ​dothe​lial
cells [119]. LSECs clear sol​u​ble waste in ​clud ​ing hyaluro ​nan
[120–123], ad ​vanced gly ​ca​tion end-prod ​ucts [109,124,125], im​mune
com​plexes [126], col​la​gen al​pha-chains [127,128], oxLDL [129] or
nano-par ​ti​cles (<200​nm) such as viruses [111] and quan ​tum dots
[130] via clathrin me​di​ated en ​do​cy ​to ​sis, while the liver res ​i​dent
macrophages (Küpf ​fer cells) clear par ​tic​u​late mat​ter larger than
200​nm [110]. This di​vi​sion of labour is called the “dual-cell prin ​ci​ple
of waste clear ​ance”, a con ​cept first in ​tro ​duced by Sørensen et al.
[110]. With the si​nu​soidal sur​face area equal to the size of a ten ​nis
court, the liver si​nu​soid is the most po​tent scav​eng ​ing sys ​tem in the
body. Con​se​quently, the LSEC has be​come the bane of nano-par ​ti​cle
and an ​ti​sense oligonu ​cleotide based ther ​a​pies that aim to tar ​get other
tis ​sues [131], but it can be an ad ​van ​tage if the liver si​nu​soid it​self is
the tar ​get.
4.2. Aging LSECs
LSECs un​dergo mor ​pho​log ​i​cal and func​tional trans ​for ​ma​tions in
dis ​ease and ag ​ing. One key change is the loss of fen ​es ​tra​tions, termed
“de​fen ​es ​tra​tion”, of ​ten as ​so​ci​ated with the de​po​si​tion of a base​ment
mem​brane [132]. “Cap ​il​lar ​iza​tion” is the term used to de​scribe the
com​bi​na​tion of de​fen ​es ​tra​tion, base​ment mem​brane syn​the​sis and al​-
tered ex ​pres ​sion of en ​dothe​lial pro ​teins which are seen in var ​i​ous
chronic liver dis ​eases in ​clud ​ing cir ​rho ​sis [133], pri​mary bil​iary cir ​-
rho ​sis [134], chronic he​pati​tis [108], and vi​ral in ​fec​tions [135].
“Pseudo​cap ​il​lar ​iza​tion” is the term used to de​scribe sim​i​lar, but dis ​-
tinct age-re​lated changes which oc​cur in the LSEC with​out the sig​nif
Fig. 1. Drugs that de​lays the ag ​ing process con ​verge on nu​tri​ent sens ​ing ef ​fec​tors in the liver. Resver ​a​trol, Met​formin, Ra​pamycin act​ing on AMPK, mTOR and Sir​tuin path ​-
ways to reg ​u ​late ISS and glu ​cose me​tab ​o​lism. All path ​ways pro ​moted are he​patic. Abbreviations: ACC: acetyl-CoA carboxylase; CHREBP: carbohydrate-responsive
element-binding protein; CRTC: creb regulated transcription co-activator 1; E4-BP4: E4 promoter–binding protein 4; FOXO1: forkhead box protein O1; GFAT: glutamine
fructose-6-phosphate amidotransferase; GLUT-4: glucose transporter, type 4; HIF-1α: hypoxia induction factor 1α; IRS1: insulin receptor substrate 1; LXR: liver X receptor;
MDC: macrophage-derived chemokine; PCAM-1: platelet endothelial cell adhesion molecule 1; PFKFB: 6-phosphofructo-2-kinase/​fructose-2,6-bisphosphatase: PGC-1α:
peroxisome proliferator-activated receptor gamma co-activator 1α; PPARα: peroxisome proliferator-activated receptor α; S6K: ribosomal protein S6 kinase; SREBP; sterol
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Fig. 2. Loss of fil​tra​tion and fen ​es ​tra​tions in ag ​ing mice, schematic of fil​tra​tion of
lipopro ​teins, in ​sulin and drugs to pass through the blood-liver mem​brane with scan​-
ning elec​tron mi​croscopy im​ages demon ​strat​ing de​fen ​es ​tra​tion.
i​cant stel​late cell ac​ti​va​tion or bridg ​ing fi​bro​sis seen with chronic
liver dis ​ease [20,24,25,91,136–140]. Ag​ing is also as ​so​ci​ated with
mor ​pho​log ​i​cal and/​or func​tional changes with the other cells of the
he​patic si​nu ​soid, namely stel​late cells and Küpf ​fer cells [21]. LSECs
in old age had markedly re​duced poros ​ity (% of LSEC sur​face area
per ​fo ​rated by fen ​es ​tra​tions) as ​so​ci​ated with in ​creased cross-sec​tional
thick ​ness of the LSEC in a va​ri​ety of species from mice to hu​mans.
These age-re​lated mor ​pho​log ​i​cal changes are ac​com​pa​nied by al​tered
ex ​pres ​sion of many vas ​cu ​lar pro ​teins in ​clud ​ing von Wille​brand’s fac​-
tor, ICAM-1, laminin, cave​olin-1 and var ​i​ous col​la​gens on LSEC and
in the space of Disse [141] but with​out other fea​tures of liver dis ​eases
[142]. Thre is re​duced scav​eng ​ing ca​pac​ity in old mice [143] at the
level of en ​do​cy ​to ​sis, as old LSECs were able to de​grade en ​do​cy ​tosed
lig ​and equally well as young LSECs once it was en ​do​cy ​tosed. How ​-
ever, there was no ap ​par ​ent age-re​lated change in the amount of the​
re​cep ​tors re​spon​si​ble for en ​do​cy ​to ​sis (sta​bilin-1 and -2 scav​enger re​-
cep ​tors), so it was con ​cluded that thick ​en ​ing of LSEC was re​tard ​ing
the trans ​port of in ​ter ​nal​ized lig ​and to the endo/​lyso​so​mal com​part​-
ment thus slow ​ing the en ​do​cytic process – the “traf ​fic jam” hy​poth ​e​-
sis [143]. De​spite the loss of ap ​prox ​i​mately one third of their en ​do​-
cytic ca​pac​ity, LSEC re​main po​tent scav​engers in ag ​ing liv ​ers.
4.3. Implications of age- ​related defenestration
Age-re​lated loss of fen ​es ​tra​tions has a sig​nif ​i​cant im​pact on the
trans ​fer of sub​stances across the en ​dothe​lium (Fig. 2). Fen​es ​tra​tions
al​low pas ​sage of smaller lipopro ​teins in ​clud ​ing chy ​lomi​cron rem​-
nants, while ex ​clud ​ing larger par ​ti​cles such as chy ​lomi​crons and
platelets. Old age is as ​so​ci​ated with im​paired he​patic clear ​ance of
chy ​lomi​cron rem​nants and the clin ​i​cal man ​i​fes ​ta​tion of post​pran ​dial
hy​per ​triglyc​eridemia. The lat​ter is more closely as ​so​ci​ated with ad ​-
verse car ​dio ​vas ​cu ​lar out​comes in older peo ​ple than clas ​si​cal dys ​lip ​i​-
daemias [136]. Us ​ing the mul​ti​ple in ​di​ca​tor di​lu ​tion method in per ​-
fused rat liv ​ers, [24] it was shown that the trans ​fer of lipopro ​teins
(av ​er ​age di​am​e​ter 53​nm) across the LSEC was al​most to ​tally abol​-
ished in liv ​ers from old rats. This pro ​vides a novel mech ​a​nism for
age-re​lated dys ​lipi​demia and post​pran ​dial hy​per ​lip ​i​daemia [24] and
may be a sig​nif ​i​cant con ​trib ​u​tor to age-re​lated hy​per ​lip ​i​daemia [144]
and, hence, vas ​cu ​lar dis ​ease.
Old age is also as ​so​ci​ated with in ​sulin re​sis​tance and a marked in ​-
crease in di​a​betes mel​li​tus. Us ​ing mul​ti​ple in ​di​ca​tor di​lu ​tion meth ​ods
in per ​fused liv ​ers, [25] it was demon ​strated that in ​sulin trans ​fer
across LSEC is im​paired in old age. Older rats showed a sig​nif ​i​cant
re​duc​tion in the he​patic vol​ume of in ​sulin dis ​tri​b​u​tion, con ​sis​tent
with the re​stric​tion of in ​sulin to the vas ​cu ​lar space. This was con ​-
firmed by whole an ​i​mal in ​sulin and glu ​cose up​take stud​ies which
showed re​duced he​patic in ​sulin up​take and con ​comi​tant re​duced ac​ti​-
va​tion of the in ​sulin re​cep ​tor sub​strate 1 and in ​sulin path ​ways in old
rats. Mea​sure​ments of glu ​cose tol​er ​ance, HOMA-IR, blood lev ​els of
in ​sulin, C-pep ​tide and glucagon showed that the re​duced in ​sulin ac​-
tion in the liver was as ​so​ci​ated with sys ​temic im​pair ​ment of in ​sulin
and glu ​cose me​tab ​o​lism [25]. These find ​ings re​veal that fen ​es ​tra​tions
in ​flu ​ence he​patic in ​sulin up​take. Con​versely, PDGF-B de​fi​cient mice
have in ​creased fen ​es ​tra​tions which was as ​so​ci​ated with in ​creased
trans-en ​dothe​lial trans ​port, dra​mat​i​cally lower cir ​cu ​lat​ing in ​sulin lev ​-
els, in ​creased in ​sulin clear ​ance and im​proved in ​sulin sen​si​tiv ​ity [145].
Ag​ing is as ​so​ci​ated with im​paired he​patic me​tab ​o​lism and elim​i​-
na​tion of many drugs, usu​ally in ​creas ​ing the risk of dose-de​pen ​dent
ad ​verse drug re​ac​tions [26]. The re​duc​tion in he​patic drug me​tab ​o​-
lism with ag ​ing [146] can in part be ex ​plained by changes in the
trans-en ​dothe​lial trans ​port of drugs across the liver si​nu​soid [147].
For ex ​am​ple, he​patic sin​gle pass clear ​ance of ac​eta​minophen is re​-
duced in ag ​ing rats sec​ondary partly to pseudo ​cap ​il​lar ​iza​tion of the
LSEC [148,149]. This may ex ​plain the age-re​lated de​crease in sus ​-
cep ​ti​bil​ity to parac​eta​mol-in ​duced he​pa​tox ​i​c​ity but the in ​crease in
nephro ​tox ​i​c​ity.
There​fore strate​gies that main ​tain fen ​es ​tra​tion poros ​ity dur ​ing ag ​-
ing, or in ​crease fen ​es ​tra​tions in older peo ​ple have the po​ten ​tial to im​-
prove dys ​lipi​demia and he​patic in ​sulin re​sis​tance, thereby pro ​vid ​ing
a novel ap ​proach for the treat​ment and pre​ven ​tion of car ​diometa​bolic
risk fac​tors in older peo ​ple [150].
5. Novel targets to reduce liver aging
In or ​der to dis ​cover drug tar ​gets that main ​tain fen ​es ​tra​tions into
old age, it is nec​es ​sary to un​der ​stand the prox ​i​mate bi​o​log ​i​cal
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creas ​ing fen ​es ​tra​tions are vas ​cu ​lar en ​dotheial growth fac​tor (VEGF)
and var ​i​ous actin cy ​toskele​ton dis ​rup ​tors [151]. These are mech ​a​nis ​-
ti​cally linked be​cause VEGF acts via its ef ​fects on the actin cy ​-
toskele​ton [152]. A ma​jor con ​cep ​tual ad ​vance oc​curred when 3D-
struc​tured il​lu ​mi​na​tion su​per res ​o​lu ​tion mi​croscopy was used to vi​su​-
al​ize LSECs [112], re​veal​ing the mor ​pho​log ​i​cal re​la​tion ​ship be​tween
fen ​es ​tra​tions and lipid rafts. It was shown that sieve plates (which are
clus ​ters of con ​tain ​ing 10-100 fen ​es ​tra​tions) were in ​ter ​ca​lated be​-
tween thick ​ened ar ​eas of mem​brane iden ​ti​fied as lipid rafts [112].
Dis​rup ​tion of lipid rafts and/​or actin cy ​toskele​ton in ​creased fen ​es ​tra​-
tions while de​ple​tion of non-raft mem​brane de​creased fen ​es ​tra​tions.
Agents that de​pleted non-raft mem​brane pre​vented actin dis ​rup ​tors
from in ​creas ​ing fen ​es ​tra​tions, thereby prov ​ing that actin dis ​rup ​tion
in ​creases fen ​es ​tra​tions di​rectly by its ef ​fects on mem​brane rafts.
VEGF both de​pleted lipid rafts and in ​creased fen ​es ​tra​tions [115]
[153]. The re​sults are con ​sis​tent with a ‘sieve-raft’ in ​ter ​ac​tion model,
where fen ​es ​tra​tions form in non-raft re​gions of en ​dothe​lial cells once
the mem​brane-sta​bi​liz​ing ef ​fects of actin cy ​toskele​ton and mem​brane
rafts are di​min ​ished [154]. The sieve-raft model pro ​vides a uni​fy ​ing
mech ​a​nis ​tic path ​way for the ef ​fects of drugs and other agents that
have been re​ported to in ​crease or de​crease fen ​es ​tra​tions (Fig. 3).
Pre​ven ​tion of age-re​lated de​fen ​es ​tra​tion has been achieved ei​ther
by us ​ing agents that act on nu​tri​ent sens ​ing path ​ways and de​lay ag ​ing
more gen ​er ​ally; and those that act on spe​cific path ​ways that ap ​pear to
reg ​u​late fen ​es ​tra​tions di​rectly. So far two drugs that de​lay ag ​ing
process have been ex ​am​ined and shown to pre​vent age-re​lated de​fen ​-
es ​tra​tion: resver ​a​trol and met​formin.
Resver ​a​trol, which acts on the sir​tuin nu​tri​ent sens ​ing path ​way,
has been shown to in ​crease fen ​es ​tra​tions in a Werner Syn​drome
mouse, which is a model for pre-ma​ture ag ​ing [155]. Met​formin,
which acts on the AMPK nu​tri​ent sens ​ing path ​way, in ​creased fen ​es ​-
tra​tion poros ​ity in old mice and im​proved HOMA-IR and in ​sulin sen​-
si​tiv ​ity [156].
A num​ber of agents that act di​rectly on the path ​ways as ​so​ci​ated
with the reg ​u​la​tion of fen ​es ​tra​tions as de​scribed above have been
tested for their ef ​fects on age-re​lated de​fen ​es ​tra​tion. The sero ​tonin re​-
cep ​tor ag ​o​nist, 2,5-dimethoxy-4-iodoam​phet​a​mine (DOI) pro ​moted
in ​creased poros ​ity in young LSECs in vitro [157], as well as in old
mice in vivo [158]. The ef ​fects of DOI were shown to be mod ​u​lated
by both VEGF de​pen ​dent and in ​de​pen ​dent mech ​a​nisms. Re​cent data
[159] have demon ​strated the util​ity of mul​ti​ple phar ​ma​ceu ​ti​cal agents
in pro ​mot​ing in ​creased fen ​es ​tra​tion di​am​e​ter and fre​quency in iso ​-
lated LSECs from both young and old mice. These agents all act via
the path ​ways pre​vi​ously dis ​cussed in this re​view: ni​tric ox​ide de​pen ​-
dent path ​ways (silde​nafil and am​lodip ​ine); NAD  pro ​mo ​tion (nicoti​-
namide mononu ​cleotide); and cell sur​face death re​cep ​tor ac​ti​va​tion
(TRAIL) [159].
Lastly, the use of statins has also been shown to pro​mote im​prove​-
ment of au ​tophagy in the set​ting of liver dis ​eases [53,160–162].
While these drugs have not been specif ​i​cally tested for this pur ​pose
in ag ​ing pre​vi​ous find ​ings sug​gest statin treat​ment may im​prove
LSEC func​tion through the pro ​mo ​tion of KLF-2 sim​i​larly to SIRT1
[70] and war​rant fur ​ther in ​ves ​ti​ga​tion.
5.1. Nanoparticles target the LSEC
A fun ​da​men ​tal chal​lenge in de​vel​op​ing phar ​ma​cother ​a​pies is tar ​-
get​ing the ac​tive agent to the de​sired cell type or tis ​sue. For​tu ​nately,
LSECs have unique prop ​er ​ties that can be ex ​ploited as a dru ​gable tar ​-
get. The LSEC is the most ac​tive and ef ​fi​cient en ​do​cytic cell in the
body [163] and is densely pop​u​lated with clathrin coated vesi​cles and
nu​mer ​ous en ​do​cytic re​cep ​tors (e.g. man ​nose re​cep ​tors, sta​bilin re​cep ​-
tors, Fc gamma-re​cep ​tor IIb2 [122,127,164,165]). This en ​do​cytic ma​-
chin ​ery is highly ef ​fi​cient in up​take and degra​da​tion of en ​doge​nous
and ex ​oge​nous waste ma​te​r​ial, in ​clud ​ing all ma​jor classes of bi​o​log ​i​-
cal macro ​mol​e​cules. There​fore, it is not sur​pris ​ing that the LSEC has
also proven to be tar ​get for the up​take of nanopar ​ti​cles, par ​tic​u​larly
those with a di​am​e​ter be​tween 5-20​nm. [130,166,167]. There​fore
nanopar ​ti​cles have been pro ​posed as an ef ​fi​cient way of de​liv ​er ​ing
drugs to the LSEC and other liver cells [168,169] (Fig. 3), re​duc​ing
dosages, off-tar ​get ef ​fects and ad ​verse drug re​ac​tions. Such drug de​-
liv ​ery tech ​nol​ogy would be ideal for ther ​a​peu ​tic agents that reg ​u​late
fen ​es ​tra​tions in the LSEC.
5.2. Methods for targeted delivery to LSECs
Sev​eral lig ​ands and/​or nanopar ​ti​cles have been in ​ves ​ti​gated for
their abil​ity to se​lec​tively tar ​get the LSEC with a va​ri​ety of drugs and
ther ​a​peu ​tic aims.
5.2.1. Specific ligands
Hyaluronic acid (HA) is in ​ter ​est ​ing be​cause the ex ​pres ​sion of its
en ​do​cytic re​cep ​tor, sta​bilin-2, is re​stricted to LSECs [170], and the
vast ma​jor ​ity of HA is cleared by the liver. HA is found within the
ex ​tra​cel​lu ​lar ma​trix and syn​ovial flu ​ids of most hu​man tis ​sues, and
HA is known to be bio ​com​pat​i​ble, degrad ​able and non-toxic [171]. A
re​cent study uti​lized HA-bound nanopar ​ti​cles in com​bi​na​tion with
gly ​cyrrhetinic acid (binds to gly ​cyrrhetinic acid re​cep ​tors ex ​pressed
on he​pa​to ​cytes) to pro ​mote tar ​get​ing within the liver [172]. HA-drug
con ​ju ​ga​tion has been suc​cess ​fully de​vel​oped for the de​liv ​ery of an ​ti​-
cancer drugs to the liver [173,174]. also It has been pointed out that
an ex ​ten ​sive range of sub​strates (e.g. nanopar ​ti​cles, nanogels, quan ​-
tum dots, hy​dro ​gels and or ​ganic mol​e​cules) have been bound to HA
to tar ​get dif ​fer ​ent can ​cer types. Sev​eral car ​ri​ers with a high affin ​ity ​
Fig. 3. The sieve-raft model of the reg ​u​la​tion of fen ​es ​tra​tions, in ​di​cat​ing where agents that act on fen ​es ​tra​tions have their ef ​fects. QDs could be used to de​liver these agents
specif ​i​cally to the LSEC in vivo. Abbreviations: 5HTR: serotonin receptor; 7KC: 7-ketocholesterol; DR4: death receptor 4; DOI: 2,5-Dimethoxy-4-iodoamphetamine; ETR:
endotheial receptor; KLF2: Krüppel-like Factor 2; MLCK: myosin light chain kinase; oxLDL: oxidised low density lipoprotein; PDE5: phosphodiesterase type 5; TRAIL:
+
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for sta​bilin re​cep ​tor 2 and man ​nose re​cep ​tors (HA, oleyamine and
poly ​sac​cha​ride chon ​droitin sul​fate) on LSECs were found to fa​cil​i​tate
tar ​geted de​liver of miRNA to re​duce murine colon can ​cer metas ​ta​sis
[175].
Chem​i​cally mod ​i​fied cy ​tokines with nat​ural lig ​ands can tar ​get
var ​i​ous liver cell types. IL-10 con ​ju ​gated with thio ​phos ​gene-ac​ti​-
vated man ​nose-6-phos ​phate in ​creased liver up​take com​pared to in ​tra​-
venous in ​jec​tions of IL-10 alone which ac​cu ​mu ​lated in the kid ​neys
[176]. Re​cep ​tors for man ​nose/​N-acetyl glu ​cosamine re​cep ​tors are ex ​-
pressed on he​pa​to ​cytes, he​patic satel​lite cells, Küpf ​fer cells and
LSECs [169].
Formalde​hyde-treated serum al​bu​min (FSA) may have po​ten ​tial
for drug de​liv ​ery to the LSEC be​cause it is avidly taken up by LSECs
in vitro and in vivo [177]. In vivo, FSA was al​most en ​tirely en ​do​cy ​-
tosed via sta​bilin-2 re​cep ​tors in the LSEC with only 2% of the dose
taken up by other tis ​sues. [178]. FSA is rapidly en ​do​cy ​tosed by
LSECs within 5-10 mins of in ​tra​venous in ​jec​tion and is de​graded
with​out he​patic or LSEC tox ​i​c​ity [110,179].
5.2.2. Nanoparticles and quantum dots
Nanopar ​ti​cles range in size from 1-500 nm (by de​f ​i​n​i​tion, one di​-
men ​sion must be within 1-100​nm). Nanopar ​ti​cles demon ​strate (i)
high motil​ity in a free state, (ii) high sur​face area, and (iii) may ex ​-
hibit quan ​tum ef ​fects. Quan ​tum dots (QDs) are a type of nanopar ​ti​cle
that ex ​hibits quan ​tum ef ​fects and have a re​stricted size (1-20​nm).
QDs are semi​con ​duc​tor par ​ti​cles that have dif ​fer ​ent op​ti​cal and con ​-
duc​tive prop ​er ​ties than larger sized par ​ti​cles. Nanopar ​ti​cle and QD
up​take within the liver is di​rected by sev​eral prop ​er ​ties: size, com​po​-
si​tion and ad ​di​tional con ​ju ​gated fac​tors. It has been shown us ​ing Cd/​
Me QDs, that nanopar ​ti​cles with a di​am​e​ter of 3-4​nm are en ​do​cy ​-
tosed en ​tirely by LSECs [130]. By com​par ​i​son, poly ​eth ​yl​ene gly ​col
(PEG)-bound nanopar ​ti​cles with a di​am​e​ter of 50 nm are taken up by
he​pa​to ​cytes [169]. PEG pro ​motes greater hy​drophilic bind ​ing and re​-
duces plasma pro ​tein bind ​ing within the cir ​cu ​la​tion, which re​duces
phago ​cy ​to ​sis by Küpf ​fer cells. In ​stead PEG binds to man ​nose/​N-
acetyl glu ​cosamine re​cep ​tors ex ​pressed on he​pa​to ​cytes, LSECs and
Küpf ​fer cells lead ​ing to en ​do​cy ​to ​sis pri​mar ​ily by he​pa​to ​cytes [169].
γ-Fe O  QDs en ​cap ​su​lated within a mod ​i​fied PEG poly ​mer were
found to un​dergo fa​cil​i​tated en ​do​cy ​to ​sis into a ED25 cell line; futhur ​-
more the use of a poly ​meric mi​celles was shown to ame​lio ​rate tox ​i​c​-
ity in ​duced by Fe O  QDs .
Ba​sic nanopar ​ti​cles with a di​am​e​ter of >250​nm are taken up pref ​-
er ​en ​tially by Küpf ​fer cells [180,181]. This is be​cause nanopar ​ti​cles of
this di​am​e​ter are too large to pass through fen ​es ​tra​tions for he​pa​to ​-
cyte up​take; in ​stead they re​main in the si​nu​soidal lu ​men. Küpf ​fer
cells gen ​er ​ally phago ​cy ​tose par ​ti​cles rang ​ing in size from 150-300​nm
in di​am​e​ter [182]. How ​ever, Küpf ​fer cells and LSECs took up 50%
of nanocrys ​tals mod ​i​fied with DSPE-PEG  that had a di​am​e​ter of
just 4-8​nm [183]. It ap ​pears that both the size and com​po​si​tion of
nanopar ​ti​cles de​ter ​mine which cell type is pref ​er ​en ​tially tar ​geted
[174].
Mer​cap ​to ​suc​cinic acid-capped cad ​mium tel​luride/​cad ​mium sul​-
fide (CdTe/​CdS) quan ​tum dots (QDs) have pre​vi​ously been shown to
ac​cu ​mu ​late se​lec​tively in the LSEC with min ​i​mal en ​do​cy ​to ​sis by
Küpf ​fer cells fol​low ​ing in ​tra​venous in ​jec​tions in vivo in rats [130].
CdTe/​CdS QDs are neg ​a​tively charged nanopar ​ti​cles that are en ​do​cy ​-
tosed by scav​enger re​cep ​tors on LSECs and Küpf ​fer cells [130]. The
lim​i​ta​tion of these QDs was the failed clear ​ance via the bile three
hours post treat​ment: this was sug​gested to con ​tribute to their tox ​i​c​ity
in LSECs.
Iron ox​ide nanocrys ​tals or Cd-Se​lenide/​CdS/​Zinc-S (core, shell,
shell) QDs en ​cap ​su​lated in a am​phiphilic poly ​mer (poly(maleic an ​hy
dride-alt-1-oct​dencene)) have been used to pro ​mote se​lec​tive up​take
into the liver, par ​tic​u​larly LSECs [184]. These nanopar ​ti​cles were
non-toxic four weeks post-in ​jec​tion with no changes in cell death de​-
tected with a TUNEL as ​say [184]. How ​ever, pre​vi​ous stud​ies with
iron ox​ide nanocrys ​tals high ​lighted cel​lu ​lar changes in actin and
tubu ​lin, and low doses of iron may pro ​mote cel​lu ​lar stress path ​ways
based on stud​ies per ​formed in HU ​VECs [185].
Lipophilic, hy​dropho ​bic HA-based nanocap ​sules tar ​get LSECs
with ap ​par ​ently less tox ​i​c​ity than other nanopar ​ti​cles [186]. These
nanocap ​sules se​lec​tively tar ​get LSECs and pul​monary mi​crovas ​cu ​lar
en ​dothe​lial cells. The nanocap ​sules con ​sist of a liq ​uid oil (oleic acid)
core sta​bi​lized by hy​dropho ​bic mod ​i​fied HA. The struc​ture is be​-
tween 100-150​nm in di​am​e​ter and sta​ble for 15 months in vivo. Both
in ​tra​venous and oral forms of ad ​min ​is ​tra​tion were ob​served to pro ​-
mote ac​cu ​mu ​la​tion within the liver within 1​h for in ​tra​venous and
within 6​ho for oral de​liv ​ery. Clear ​ance was con ​firmed in urine of the
sta​ble nanocap ​sule 6​h post ad ​min ​is ​tra​tion with min ​i​mal ex ​pres ​sion in
plasma. These char ​ac​ter ​is ​tics were con ​sid​ered by the au ​thors to be fa​-
vor ​able for drug de​liv ​ery to the liver.
An​other in ​ter ​est ​ing nanopar ​ti​cle for the de​liv ​ery of agents to the
LSEC is MEND (mul​ti​func​tional en ​ve​lope-like nanocap ​sule de​vice).
This nanopar ​ti​cle is com​posed of cho ​les ​terol and PEG-DMG (1, 2-
dimyris ​toyl-sn-glyc​ero, methoxy eth ​yl​ene gly ​col 2000 ether) com​-
bined with a cationic lipid (YSK05) to fa​cil​i​tate the en ​do​so​mal es ​-
cape of MEND. MEND is tar ​geted to LSECs and he​pa​to ​cytes via
steary ​lated KLGR, a novel LDL re​cep ​tor mol​e​cule [187] and its 84-
118​nm di​am​e​ter. This nanopar ​ti​cle has been used to de​liver siRNA to
down​reg ​u​late Tie2 ex ​pres ​sion in he​pa​to ​cytes and LSECs [188] and
has been shown to acts via mi​cropinocy ​to ​sis rather than clathrin-me​-
di​ated en ​do​cy ​to ​sis.
6. Summary
Path​ways that reg ​u ​late the meta​bolic re​sponses to nu​tri​tion by the
liver are a plau ​si​ble tar ​get for de​lay ​ing ag ​ing. Di​ets and drugs that in ​-
flu ​ence the canon ​i​cal nu​tri​ent sens ​ing path ​ways in the liver are be​ing
ex ​ten ​sively stud​ied. How ​ever, there are also age-re​lated changes in
the liver mi​cro ​cir ​cu ​la​tion that in ​flu ​ence the reg ​u​la​tion of me​tab ​o​lism
by the liver, par ​tic​u​larly the me​tab ​o​lism of lipopro ​teins and in ​sulin
sen​si​tiv ​ity. There are sev​eral drugs and other agents that can in ​crease
fen ​es ​tra​tions in LSECs from old an ​i​mals. Such agents, cou ​pled to
nanopar ​ti​cles that are se​lec​tively taken up by LSECs, may prove to
be a novel ther ​a​peu ​tic tar ​get for the pre​ven ​tion and treat​ment of age-
re​lated dys ​lipi​demia and in ​sulin re​sis​tance.
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